A detailed history of Northwest Capital Management Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Northwest Capital Management Inc holds 1,427 shares of ABBV stock, worth $254,020. This represents 0.1% of its overall portfolio holdings.

Number of Shares
1,427
Previous 1,427 -0.0%
Holding current value
$254,020
Previous $281,000 -0.0%
% of portfolio
0.1%
Previous 0.1%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 09, 2024

SELL
$154.79 - $180.76 $66,095 - $77,184
-427 Reduced 23.03%
1,427 $244,000
Q4 2023

Feb 01, 2024

SELL
$137.6 - $154.97 $25,731 - $28,979
-187 Reduced 9.16%
1,854 $287,000
Q1 2023

May 03, 2023

BUY
$144.61 - $166.54 $49,890 - $57,456
345 Added 20.34%
2,041 $325,000
Q4 2022

Feb 02, 2023

SELL
$138.31 - $165.87 $55,324 - $66,348
-400 Reduced 19.08%
1,696 $274,000
Q3 2022

Nov 07, 2022

BUY
$134.21 - $153.93 $13,689 - $15,700
102 Added 5.12%
2,096 $281,000
Q2 2022

Aug 02, 2022

SELL
$137.62 - $174.96 $6,192 - $7,873
-45 Reduced 2.21%
1,994 $305,000
Q1 2022

May 10, 2022

SELL
$131.98 - $163.75 $7,258 - $9,006
-55 Reduced 2.63%
2,039 $331,000
Q4 2021

Feb 07, 2022

SELL
$107.43 - $135.93 $12,569 - $15,903
-117 Reduced 5.29%
2,094 $295,000
Q3 2021

Oct 25, 2021

SELL
$106.4 - $120.78 $83,524 - $94,812
-785 Reduced 26.2%
2,211 $241,000
Q2 2021

Aug 02, 2021

BUY
$105.21 - $117.21 $38,296 - $42,664
364 Added 13.83%
2,996 $348,000
Q1 2021

May 10, 2021

BUY
$102.3 - $112.62 $1,227 - $1,351
12 Added 0.46%
2,632 $285,000
Q4 2020

Feb 09, 2021

BUY
$80.49 - $108.67 $965 - $1,304
12 Added 0.46%
2,620 $281,000
Q3 2020

Nov 10, 2020

BUY
$85.91 - $100.83 $1,030 - $1,209
12 Added 0.46%
2,608 $228,000
Q2 2020

Jul 24, 2020

BUY
$73.37 - $98.18 $190,468 - $254,875
2,596 New
2,596 $255,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $315B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Northwest Capital Management Inc Portfolio

Follow Northwest Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northwest Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Northwest Capital Management Inc with notifications on news.